Kairos Pharma, Ltd. (KAPA)
NYSEAMERICAN: KAPA · Real-Time Price · USD
0.3182
+0.0082 (2.65%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Kairos Pharma Employees
As of December 31, 2025, Kairos Pharma had 4 total employees, including 1 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,459,750
Market Cap
6.81M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | 0 | - | 1 | 3 |
| Dec 31, 2024 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| BioAtla | 41 |
| CollPlant Biotechnologies | 39 |
| Processa Pharmaceuticals | 12 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 5 |
| Can-Fite BioPharma | 5 |
| Cadrenal Therapeutics | 5 |
| Acurx Pharmaceuticals | 4 |
KAPA News
- 5 days ago - CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever - Newsfile Corp
- 5 days ago - Kairos Pharma announces interim safety data from Phase 1 trial of ENV-105 - TheFly
- 5 days ago - Kairos Pharma Reports Breakthrough Interim Safety Data in Phase 1 Trial of ENV-105 in EGFR-Mutated Lung Cancer Patients — Targeting a $10 Billion Drug Resistance Market - Business Wire
- 21 days ago - Kairos Pharma Transcript: AGM 2026 - Transcripts
- 4 weeks ago - Kapa Gold Announces the Results of Its 2026 Annual General Meeting - Newsfile Corp
- 6 weeks ago - Kairos Pharma issues letter from CEO that recaps year, details plans for 2026 - TheFly
- 6 weeks ago - Kairos Pharma Recaps Important Acquisitions and Details Plans for the Balance of 2026 in Letter to Shareholders - Business Wire
- 7 weeks ago - Kairos Pharma Proxy statement: Proxy filing - Filings